Summit Therapeutics Inc. (SMMT) — Executive Compensation
Fiscal year ended December 2025
This page summarizes Summit Therapeutics Inc. (SMMT) named executive officer compensation from the most recent SEC DEF 14A proxy statement. Robert W. Duggan (CEO) received $172,376 in reported total compensation@if($peoPaid !== null), with $172,376 "actually paid" under the SEC pay-versus-performance rule. @endif Total shareholder return for the period was 372.13.
Named executive officers — fiscal year ended December 2025
| Name | Role | Reported total | Actually paid |
|---|---|---|---|
| Robert W. Duggan | CEO | $172,376 | $172,376 |
| Mahkam Zanganeh | Former CEO | $246,047,279 | $233,109,816 |
Frequently asked questions
- Who is the CEO of SMMT and how much are they paid?
- Robert W. Duggan serves as CEO of Summit Therapeutics Inc.. For fiscal year ending December 2025, reported total compensation was $172,376.
- What is included in executive compensation?
- SEC Summary Compensation Table figures include base salary, cash bonuses, stock awards (grant-date fair value), option awards, non-equity incentive plan compensation, pension value changes, and all other compensation. "Actually Paid" compensation follows the newer SEC pay-versus-performance rule and reflects realized value.
- What is pay-versus-performance?
- The SEC pay-versus-performance disclosure requires companies to show the relationship between executive pay "actually paid" and total shareholder return (TSR) over recent fiscal years, so investors can evaluate pay alignment.